Trial Profile
A double-blind, placebo-controlled, escalating-dose study of the effect of N-003 on renal function, pharmacodynamics, pharmacokinetics, safety and tolerability in patients with advanced liver disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Noorik Biopharmaceuticals
- 25 May 2018 Status changed from recruiting to discontinued.
- 23 Nov 2016 New trial record